Concepedia

Gilbert Wagener

GW

Statistics

Publications

15

Citations

1.5K

H-Index

14

Active since

1992

Affiliations

Bayer (Germany)(Current)

University of Cambridge

Hôpitaux Universitaires Henri-Mondor

Maastricht University Medical Centre

University of Milano-Bicocca

Gilbert Wagener is an author at Bayer (Germany) specializing in clinical pharmacology, pharmacology, and cardiovascular pharmacotherapy.

Publications per year

1992–2021

15

Publications

15

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial

Philip A. Poole‐Wilson, Jacobus Lubsen, Bridget‐Anne Kirwan et al. · The Lancet · 2004 · 518 citations

, , +9

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

Mary P. McGowan, Jean‐Claude Tardif, R Češka et al. · PLoS ONE · 2012 · 224 citations · Full text

, , +17

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

Maartje E. Visser, Gilbert Wagener, Brenda F. Baker et al. · European Heart Journal · 2012 · 190 citations · Full text

, , +17

Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)

Giuseppe Mancia, Morris J. Brown, A Castaigne et al. · Hypertension · 2003 · 158 citations · Full text

, , +17

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial

Jacobus Lubsen, Gilbert Wagener, Bridget‐Anne Kirwan et al. · Journal of Hypertension · 2005 · 137 citations

, , +16

1–5 of 15